title: Statins, inflammation and deep vein thrombosis: a systematic review.
abstract: Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) and pulmonary embolism. The 2009 JUPITER trial showed a significant decrease in DVT in non-hyperlipidemic patients, with elevated C-reactive protein (CRP) levels, treated with rosuvastatin. The effects of statins on thrombosis are unclear, prompting this literature review. A literature search was performed (1950 to February 2011) with MEDLINE, EMBASE, and PUBMED databases including the following keywords: "statins", "hydroxymethylglutaryl-CoA reductase inhibitors", "VTE", "PE", "DVT", and either "anti-coagulation" or "inflammation". Editorials, reviews, case reports, meta-analysis and duplicates were excluded. Inflammatory biomarkers of DVT, include interleukin (IL)-6, CRP, IL-8, and monocyte chemotactic protein 1 (MCP-1). Statin therapy reduces IL-6 expression of CRP and MCP-1, usually elevated in VTE. Reduction of IL-6 induced MCP-1 has been linked to vein wall fibrosis, promoting post thrombotic syndrome (PTS) and recurrent DVT in patients. Also, our review suggests that the anti-thrombotic effects are likely exhibited through the anti-inflammatory properties of statins. This work supports that statin therapy has the ability to decrease the incidence and recurrence of VTE and the potential to decrease PTS. This is mainly due to the anti-inflammatory effects of statins and may explain why normolipidemic patients, with elevated CRP, appear to have the greatest reduction in VTE. Given their low risk of bleeding, statins have the potential to serve as a safe adjunctive pharmacological therapy to current treatments in select patients with VTE, however further investigations into this concept are needed and essential.
authors.affiliation: Department of Surgery, Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, School of Medicine, University of Michigan, 1150 W. Medical Center Drive, Ann Arbor, MI 48109, USA.
authors.forename: April L
authors.initials: AL
authors.lastname: Rodriguez
authors.forename: Brandon M
authors.initials: BM
authors.lastname: Wojcik
authors.forename: Shirley K
authors.initials: SK
authors.lastname: Wrobleski
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Myers
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Wakefield
authors.forename: Jose A
authors.initials: JA
authors.lastname: Diaz
mesh_terms: D002097:C-Reactive Protein / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006904:Hydroxymethylglutaryl-CoA Synthase / Q000378:metabolism; D016239:MEDLINE; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000378:metabolism; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000378:metabolism; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein; D006904:Hydroxymethylglutaryl-CoA Synthase